Kelly Leary - How To Starve Cancer: Complete Guide about Cancers History, Treatment, and Prevention

HOW TO STARVE CANCER

Complete Guide about Cancer's

History, Treatment, and Prevention

Kelly Leary

Copyright by Kelly Leary All rights reserved.

This eBook is provided with the sole purpose of providing relevant information on a specific topic for which every reasonable effort has been made to ensure that it is both accurate and reasonable. Nevertheless, by purchasing this eBook, you consent to the fact that the author, as well as the publisher, are in no way experts on the topics contained herein, regardless of any claims as such that may be made within. As such, any suggestions or recommendations that are made within are done so purely for entertainment value. It is recommended that you always consult a professional prior to undertaking any of the advice or techniques discussed within.

This is a legally binding declaration that is considered both valid and fair by both the Committee of Publishers Association and the American Bar Association and should be considered as legally binding within the United States.

The reproduction, transmission, and duplication of any of the content found herein, including any specific or extended information, will be done as an illegal act regardless of the end form the information ultimately takes. This includes copied

versions of the work, both physical, digital, and audio unless express consent of the Publisher is provided beforehand. Any additional rights reserved.

Furthermore, the information that can be found within the pages described forthwith shall be considered both accurate and truthful when it comes to the recounting of facts. As such, any use, correct or incorrect, of the provided information will render the Publisher free of responsibility as to the actions taken outside of their direct purview. Regardless, there are zero scenarios where the original author or the Publisher can be deemed liable in any fashion for any damages or hardships that may result from any of the information discussed herein.

Additionally, the information in the following pages is intended only for informational purposes and should thus be thought of as universal. As befitting its nature, it is presented without assurance regarding its prolonged validity or interim quality.

Trademarks that are mentioned are done without written consent and can in no way be considered an endorsement from the trademark holder.

For decades, scientists have been trying to stop cancer by blocking nutrients from reaching tumor cells, effectively robbing

tumor cells from the food required to expand and proliferate.

These attempts have also been frustrated that cancer cells are nimble, depending on multiple contingency routes to continue to expand.

Researchers have manipulated a specific weak point in the metabolism of cancer cells, causing tumor cells to expose backup fuel supply routes on which they rely when this vulnerability is disrupted. Mapping these secondary pathways, researchers have also established drugs that block them. A major clinical study of cancer patients is currently being prepared to test this therapeutic approach.

Like a healthy cell, a sarcoma cell depends on external supplies of arginine, an essential building block of proteins. Remove environmental arginine and the cell must initiate a cycle called autophagy, or "self-eating," to live. A second attack on the survival mechanism, then destroys the cells Studying human cancer cells and the mice injected with patient tumor samples, the researchers prove that a double strike the elimination of the weak point and one of the tumor cells 'replacement pathways is effective against several hard-to-treat cancers.

While found in several forms of cancer, the weak point is especially prominent in sarcomas rare skin, muscle, bone, cartilage, and connective tissue cancers, doctors treat sarcomas mainly with conventional surgery, radiation and chemotherapy, although these therapies are sometimes not successful.

It is known that this metabolic deficiency is found in 90% of sarcomas Healthy cells may not have this flaw. We have been attempting to establish a treatment that takes advantage of the metabolic deficiency so, ideally, it can only treat the tumor.

Essentially, the mutation helps one to compel the tumor cells to die. "In order to expand and proliferate, the tumor cells must

have simple building materials. The work approach is focused on the assumption that the overwhelming majority of sarcomas have missed the capacity to produce their own arginine, a protein building block that cells use to create more of themselves. In the absence of this capacity, the cells will extract arginine from the external area. The stock of arginine in the blood is sufficient, and the cancer cells have little trouble scavenging it. But removing the environmental supply of arginine and cells is a issue.

"If we use a medication to deplete arginine in the blood, the cancer cells fear as they have depleted their fuel source," Van Tine said. "Now they're rewiring to continue and live. For this research, we used this rewiring to classify medications that block secondary pathways. "Like other cancer treatments, the loss of arginine in the blood does not impact healthy cells. Healthy cells do not depend on foreign sources of arginine since they may not have a metabolic deficiency in the cancer. We tend to produce their own arginine, but there is no mediated malnutrition in regular cells even though there is no arginine in the blood. This technique is focused on the tumor's properties specifically, it shuts down tumor metabolism and nothing else.

Unable to produce or receive external arginine, the fuel supply routes of the tumor cells are pushed inward. Cells may continue to metabolize their internal supply of arginine in a cycle called autophagy or self-eating. In the case of sarcomas, it delays or delays down the development of cancer but does not destroy the

cell. Throughout this phase, tumor cells seem to be buying time to rediscover another internal work-around.

"Cancer doesn't disappear because you interrupt the primary fuel source," Van Tine said. "Because of this, it transforms all these roads to redemption. Within this article, we established the mechanisms of salvage. And we found that when you poison them, you destroy the cells, too. Our research has shown that tumors are gradually diminishing in these conditions. It is the first time that tumors have been shown to reduce utilizing only metabolic medications with no other anti-cancer approaches.

The arginine-depleting medication is now in clinical studies evaluating its protection with efficacy against kidney, lung, pancreatic, breast and other cancers. But, to date, it has been unlikely to succeed as it has triggered the regeneration mechanisms that enable cancer growth to begin. Researchers also proposed that the medication can still be a critical mitochondrial treatment for cancer as long as it is used in conjunction with other medications targeting replacement pathways.

If cancer cells with this metabolic deficiency are depleted of environmental arginine, they are required to switch from a glucose-burning mechanism to a mechanism that consumes another fuel called glutamine. Researchers also demonstrated that the application of a glutamine receptor to the arginine-depleting product is toxic to the cells. Eliminating arginine from the blood often re-wires serine biology, another backup power, and incorporating serine inhibitors often triggers cell death.

This technique may be extended outside uncommon sarcoma tumors, since the metabolic disorder is also found in many cancers, including other forms of breast, colon, lung, brain, and bone tumors, the researchers said. The latest research provides

evidence demonstrating specific anti-tumor responses in cell lines of both forms of cancer.